Table 3. Association of miR-21, miR-221 and miR-222 expression with prostate cancer recurrence free survival and aggressiveness.

	Recurrence				Aggressiveness
	Age adjusteda HR (95% CI)	P	Multivariateb HR (95% CI)	P	OR (95% CI)	P
miR-21
All cases	3.31 (1.32–8.34)	0.011	1.99 (0.70–5.64)	0.20	1.53 (0.52–4.52)	0.45
Non-obese cases	2.26 (0.69–7.34)	0.18	1.28 (0.30–5.49)	0.74	1.80 (0.46–7.00)	0.40
Obese cases	5.40 (1.16–25.10)	0.031	6.15 (1.04–36.48)	0.045	1.20 (0.19–7.78)	0.85
miR-221
All cases	0.71 (0.32–1.61)	0.42	0.56 (0.21–1.50)	0.25	1.28 (0.47–3.50)	0.64
Non-obese cases	0.50 (0.15–1.66)	0.26	0.40 (0.09–1.84)	0.24	1.23 (0.37–4.05)	0.74
Obese cases	0.77 (0.23–2.66)	0.68	0.46 (0.10–2.22)	0.33	1.26 (0.15–10.52)	0.83
miR-222
All cases	0.51 (0.22–1.18)	0.12	0.39 (0.14–1.15)	0.09	1.62 (0.56–4.74)	0.37
Non-obese cases	0.37 (0.11–1.20)	0.10	0.37 (0.09–1.59)	0.18	1.36 (0.39–4.68)	0.63
Obese cases	0.55 (0.12–2.47)	0.44	0.46 (0.07–3.19)	0.44	2.26 (0.22–23.53)	0.50

^aAdjusted for age at diagnosis (continuous).

^bAdjusted for age at diagnosis (continuous), Gleason score (<7 vs. ≥7) and stage (1 and 2 vs. 3 and 4).